An Open-Label, Multi-Center, Expanded Access Study of RAD001 in Patients With Metastatic Carcinoma of the Kidney Who Are Intolerant of or Have Progressed Despite Any AvailableVascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Expanded Access
N/A
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CRAD001L2401
NCT00655252
Name | Location |
---|---|
Indiana University Cancer Center | Indianapolis, Indiana 46202-5265 |
Cancer Centers of the Carolinas | Greenville, South Carolina 29605 |
Missouri Cancer Associates | Columbia, Missouri 65201 |
Henry Ford Health System | Detroit, Michigan 48202 |
Cancer Centers of Florida, P.A. | Orlando, Florida |
Gabrail Cancer Center | Canton, Ohio 44718 |
Highlands Oncology Group, PA | Springdale, Arkansas 72764 |
Cleo Craig Memorial Cancer & Research Clinic | Lawton, Oklahoma 73505 |
MD Anderson Cancer Center - Orlando | Orlando, Florida 32806 |
Heartland Hematology-Oncology Associates, Inc. | Kansas City, Missouri 64118 |
University of Colorado Health Sciences Center/Anschutz Pavillion | Aurora, Colorado 12801 |
The Cancer Institute, St. Joseph Medical Center | Towson, Maryland 21209 |
Washington University/Siteman Cancer Center | St. Louis, Missouri 63110 |
Blumenthal Cancer Center/Carolinas Medical Center | Charlotte, North Carolina 28203 |
Cliveland Clinic Foundation | Cleveland, Ohio 44195 |